

Cara Haymaker

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3026306/publications.pdf>

Version: 2024-02-01

80
papers

5,982
citations

94433

37
h-index

82547

72
g-index

84
all docs

84
docs citations

84
times ranked

10305
citing authors

#	ARTICLE	IF	CITATIONS
1	Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy. <i>Cancer Discovery</i> , 2016, 6, 202-216.	9.4	1,158
2	Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial. <i>Nature Medicine</i> , 2021, 27, 504-514.	30.7	357
3	Combining Immune Checkpoint Blockade and Tumor-Specific Vaccine for Patients With Incurable Human Papillomavirus-Related Cancer. <i>JAMA Oncology</i> , 2019, 5, 67.	7.1	344
4	Validation of multiplex immunofluorescence panels using multispectral microscopy for immune-profiling of formalin-fixed and paraffin-embedded human tumor tissues. <i>Scientific Reports</i> , 2017, 7, 13380.	3.3	208
5	Identification of bacteria-derived HLA-bound peptides in melanoma. <i>Nature</i> , 2021, 592, 138-143.	27.8	187
6	A First-in-Human Study and Biomarker Analysis of NKTR-214, a Novel IL2R β -Biased Cytokine, in Patients with Advanced or Metastatic Solid Tumors. <i>Cancer Discovery</i> , 2019, 9, 711-721.	9.4	180
7	Adoptive T-Cell Therapy Using Autologous Tumor-Infiltrating Lymphocytes for Metastatic Melanoma. <i>Cancer Journal (Sudbury, Mass)</i> , 2012, 18, 160-175.	2.0	176
8	TCR Repertoire Intratumor Heterogeneity in Localized Lung Adenocarcinomas: An Association with Predicted Neoantigen Heterogeneity and Postsurgical Recurrence. <i>Cancer Discovery</i> , 2017, 7, 1088-1097.	9.4	160
9	Bempegaldesleukin (NKTR-214) plus Nivolumab in Patients with Advanced Solid Tumors: Phase I Dose-Escalation Study of Safety, Efficacy, and Immune Activation (PIVOT-02). <i>Cancer Discovery</i> , 2020, 10, 1158-1173.	9.4	158
10	Exploiting the neoantigen landscape for immunotherapy of pancreatic ductal adenocarcinoma. <i>Scientific Reports</i> , 2016, 6, 35848.	3.3	127
11	Effect of neoadjuvant chemotherapy on the immune microenvironment in non-small cell lung carcinomas as determined by multiplex immunofluorescence and image analysis approaches. , 2018, 6, 48.		126
12	Bempegaldesleukin selectively depletes intratumoral Tregs and potentiates T cell-mediated cancer therapy. <i>Nature Communications</i> , 2020, 11, 661.	12.8	124
13	Delayed maturation of an IL-12-producing dendritic cell subset explains the early Th2 bias in neonatal immunity. <i>Journal of Experimental Medicine</i> , 2008, 205, 2269-2280.	8.5	121
14	Genomic and immune heterogeneity are associated with differential responses to therapy in melanoma. <i>Npj Genomic Medicine</i> , 2017, 2, .	3.8	120
15	RNA editing derived epitopes function as cancer antigens to elicit immune responses. <i>Nature Communications</i> , 2018, 9, 3919.	12.8	120
16	Interleukin-6 blockade abrogates immunotherapy toxicity and promotes tumor immunity. <i>Cancer Cell</i> , 2022, 40, 509-523.e6.	16.8	115
17	Batf is important for IL-4 expression in T follicular helper cells. <i>Nature Communications</i> , 2015, 6, 7997.	12.8	114
18	Novel algorithmic approach predicts tumor mutation load and correlates with immunotherapy clinical outcomes using a defined gene mutation set. <i>BMC Medicine</i> , 2016, 14, 168.	5.5	106

#	ARTICLE	IF	CITATIONS
19	Prospective Analysis of Adoptive TIL Therapy in Patients with Metastatic Melanoma: Response, Impact of Anti-CTLA4, and Biomarkers to Predict Clinical Outcome. <i>Clinical Cancer Research</i> , 2018, 24, 4416-4428.	7.0	89
20	FoxP3+ROR γ t+ T Helper Intermediates Display Suppressive Function against Autoimmune Diabetes. <i>Journal of Immunology</i> , 2010, 184, 3377-3385.	0.8	81
21	Combined Analysis of Antigen Presentation and T-cell Recognition Reveals Restricted Immune Responses in Melanoma. <i>Cancer Discovery</i> , 2018, 8, 1366-1375.	9.4	80
22	Immune evolution from preneoplasia to invasive lung adenocarcinomas and underlying molecular features. <i>Nature Communications</i> , 2021, 12, 2722.	12.8	74
23	The RNA-binding Protein MEX3B Mediates Resistance to Cancer Immunotherapy by Downregulating HLA-A Expression. <i>Clinical Cancer Research</i> , 2018, 24, 3366-3376.	7.0	73
24	PD-1 and BTLA and CD8 ⁺ T-cell "exhaustion" in cancer. <i>Oncimmunology</i> , 2012, 1, 735-738.	4.6	71
25	Selective inhibition of autoimmune exacerbation while preserving the anti-tumor clinical benefit using IL-6 blockade in a patient with advanced melanoma and Crohn's disease: a case report. <i>Journal of Hematology and Oncology</i> , 2016, 9, 81.	17.0	62
26	Characterization of the Immune Landscape of EGFR-Mutant NSCLC Identifies CD73/Adenosine Pathway as a Potential Therapeutic Target. <i>Journal of Thoracic Oncology</i> , 2021, 16, 583-600.	1.1	62
27	Multifaceted Role of BTLA in the Control of CD8+ T-cell Fate after Antigen Encounter. <i>Clinical Cancer Research</i> , 2017, 23, 6151-6164.	7.0	58
28	The Effect of Topoisomerase I Inhibitors on the Efficacy of T-Cell-Based Cancer Immunotherapy. <i>Journal of the National Cancer Institute</i> , 2018, 110, 777-786.	6.3	58
29	Procedural Requirements and Recommendations for Multiplex Immunofluorescence Tyramide Signal Amplification Assays to Support Translational Oncology Studies. <i>Cancers</i> , 2020, 12, 255.	3.7	58
30	Elucidation of Tumor-Stromal Heterogeneity and the Ligand-Receptor Interactome by Single-Cell Transcriptomics in Real-world Pancreatic Cancer Biopsies. <i>Clinical Cancer Research</i> , 2021, 27, 5912-5921.	7.0	57
31	Distinct clinical patterns and immune infiltrates are observed at time of progression on targeted therapy versus immune checkpoint blockade for melanoma. <i>Oncimmunology</i> , 2016, 5, e1136044.	4.6	55
32	BTLA marks a less-differentiated tumor-infiltrating lymphocyte subset in melanoma with enhanced survival properties. <i>Oncimmunology</i> , 2015, 4, e1014246.	4.6	50
33	A case report of Grover's disease from immunotherapy-a skin toxicity induced by inhibition of CTLA-4 but not PD-1. , 2016, 4, 55.		50
34	A Novel Method to Generate and Expand Clinical-Grade, Genetically Modified, Tumor-Infiltrating Lymphocytes. <i>Frontiers in Immunology</i> , 2017, 8, 908.	4.8	50
35	Neoadjuvant Chemotherapy Increases Cytotoxic T Cell, Tissue Resident Memory T Cell, and B Cell Infiltration in Resectable NSCLC. <i>Journal of Thoracic Oncology</i> , 2021, 16, 127-139.	1.1	48
36	Activation and Propagation of Tumor-infiltrating Lymphocytes on Clinical-grade Designer Artificial Antigen-presenting Cells for Adoptive Immunotherapy of Melanoma. <i>Journal of Immunotherapy</i> , 2014, 37, 448-460.	2.4	47

#	ARTICLE	IF	CITATIONS
37	Metastatic Melanoma Patient Had a Complete Response with Clonal Expansion after Whole Brain Radiation and PD-1 Blockade. <i>Cancer Immunology Research</i> , 2017, 5, 100-105.	3.4	46
38	4-1BB-Enhanced Expansion of CD8+ TIL from Triple-Negative Breast Cancer Unveils Mutation-Specific CD8+ T Cells. <i>Cancer Immunology Research</i> , 2017, 5, 439-445.	3.4	45
39	Parallel profiling of immune infiltrate subsets in uveal melanoma versus cutaneous melanoma unveils similarities and differences: A pilot study. <i>OncoImmunology</i> , 2017, 6, e1321187.	4.6	45
40	Nodal immune flare mimics nodal disease progression following neoadjuvant immune checkpoint inhibitors in non-small cell lung cancer. <i>Nature Communications</i> , 2021, 12, 5045.	12.8	42
41	4-1BB Agonist Focuses CD8+ Tumor-Infiltrating T-Cell Growth into a Distinct Repertoire Capable of Tumor Recognition in Pancreatic Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 7263-7275.	7.0	41
42	Single-cell profiling of dynamic cytokine secretion and the phenotype of immune cells. <i>PLoS ONE</i> , 2017, 12, e0181904.	2.5	39
43	Hallmarks of Resistance to Immune-Checkpoint Inhibitors. <i>Cancer Immunology Research</i> , 2022, 10, 372-383.	3.4	36
44	Immune-Modulation by Epidermal Growth Factor Receptor Inhibitors: Implication on Anti-Tumor Immunity in Lung Cancer. <i>PLoS ONE</i> , 2016, 11, e0160004.	2.5	33
45	Utilizing T-cell Activation Signals 1, 2, and 3 for Tumor-infiltrating Lymphocytes (TIL) Expansion: The Advantage Over the Sole Use of Interleukin-2 in Cutaneous and Uveal Melanoma. <i>Journal of Immunotherapy</i> , 2018, 41, 399-405.	2.4	32
46	Tisotolimod with Ipilimumab Drives Tumor Responses in Anti-PD-1 Refractory Melanoma. <i>Cancer Discovery</i> , 2021, 11, 1996-2013.	9.4	32
47	Intrathecal Administration of Tumor-Infiltrating Lymphocytes Is Well Tolerated in a Patient with Leptomeningeal Disease from Metastatic Melanoma: A Case Report. <i>Cancer Immunology Research</i> , 2015, 3, 1201-1206.	3.4	29
48	Pilot Clinical Trial of Perioperative Durvalumab and Tremelimumab in the Treatment of Resectable Colorectal Cancer Liver Metastases. <i>Clinical Cancer Research</i> , 2021, 27, 3039-3049.	7.0	28
49	Identification of distinct immune landscapes using an automated nine-color multiplex immunofluorescence staining panel and image analysis in paraffin tumor tissues. <i>Scientific Reports</i> , 2021, 11, 4530.	3.3	27
50	Preclinical Development and First-in-Human Study of KA2507, a Selective and Potent Inhibitor of Histone Deacetylase 6, for Patients with Refractory Solid Tumors. <i>Clinical Cancer Research</i> , 2021, 27, 3584-3594.	7.0	26
51	Blood biomarkers associated to complete pathological response on NSCLC patients treated with neoadjuvant chemoimmunotherapy included in NADIM clinical trial. <i>Clinical and Translational Medicine</i> , 2021, 11, e491.	4.0	26
52	Immuno-profiling and cellular spatial analysis using five immune oncology multiplex immunofluorescence panels for paraffin tumor tissue. <i>Scientific Reports</i> , 2021, 11, 8511.	3.3	24
53	The beneficial effects of a gas-permeable flask for expansion of Tumor-Infiltrating lymphocytes as reflected in their mitochondrial function and respiration capacity. <i>OncoImmunology</i> , 2016, 5, e1057386.	4.6	22
54	Absence of Grail promotes CD8+ T cell anti-tumour activity. <i>Nature Communications</i> , 2017, 8, 239.	12.8	22

#	ARTICLE	IF	CITATIONS
55	Tumor-Infiltrating Lymphocyte Therapy for Melanoma: Rationale and Issues for Further Clinical Development. <i>BioDrugs</i> , 2014, 28, 421-437.	4.6	21
56	Fetal Exposure to High-Avidity TCR Ligand Enhances Expansion of Peripheral T Regulatory Cells. <i>Journal of Immunology</i> , 2008, 181, 73-80.	0.8	19
57	Mechanisms Underlying Antigen-Specific Tolerance of Stable and Convertible Th17 Cells During Suppression of Autoimmune Diabetes. <i>Diabetes</i> , 2012, 61, 2054-2065.	0.6	19
58	Aurora kinase inhibition sensitizes melanoma cells to T-cell-mediated cytotoxicity. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 1101-1113.	4.2	18
59	Histone Deacetylase Inhibitors and IL21 Cooperate to Reprogram Human Effector CD8+ T Cells to Memory T Cells. <i>Cancer Immunology Research</i> , 2020, 8, 794-805.	3.4	17
60	Potential clinical application of tumor-infiltrating lymphocyte therapy for ovarian epithelial cancer prior or post-resistance to chemotherapy. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 1747-1757.	4.2	16
61	Engineered T-cell Receptor T Cells for Cancer Immunotherapy. <i>Cancer Immunology Research</i> , 2021, 9, 1252-1261.	3.4	16
62	Bone Marrow-Derived IL-13R α 1 ⁺ Positive Thymic Progenitors Are Restricted to the Myeloid Lineage. <i>Journal of Immunology</i> , 2012, 188, 3208-3216.	0.8	15
63	Evolution of Genomic and T-cell Repertoire Heterogeneity of Malignant Pleural Mesothelioma Under Dasatinib Treatment. <i>Clinical Cancer Research</i> , 2020, 26, 5477-5486.	7.0	15
64	LFA-1 activation enriches tumor-specific T cells in a cold tumor model and synergizes with CTLA-4 blockade. <i>Journal of Clinical Investigation</i> , 2022, 132, .	8.2	14
65	T Cell Dynamics during Induction of Tolerance and Suppression of Experimental Allergic Encephalomyelitis. <i>Journal of Immunology</i> , 2011, 187, 3979-3986.	0.8	13
66	Diminished Immune Surveillance during Histologic Progression of Intraductal Papillary Mucinous Neoplasms Offers a Therapeutic Opportunity for Cancer Interception. <i>Clinical Cancer Research</i> , 2022, 28, 1938-1947.	7.0	11
67	Distinct Immune Gene Programs Associated with Host Tumor Immunity, Neoadjuvant Chemotherapy, and Chemoimmunotherapy in Resectable NSCLC. <i>Clinical Cancer Research</i> , 2022, 28, 2461-2473.	7.0	9
68	Next-Generation Immunotherapies to Improve Anticancer Immunity. <i>Frontiers in Pharmacology</i> , 2020, 11, 566401.	3.5	8
69	Immune Profiling Mass Cytometry Assay Harmonization: Multicenter Experience from CIMAC-CIDC. <i>Clinical Cancer Research</i> , 2021, 27, 5062-5071.	7.0	8
70	APCs Expressing High Levels of Programmed Death Ligand 2 Sustain the Development of CD4 T Cell Memory. <i>Journal of Immunology</i> , 2010, 185, 3149-3157.	0.8	7
71	Antigen-Specific Effector CD4 T Lymphocytes School Lamina Propria Dendritic Cells To Transfer Innate Tolerance. <i>Journal of Immunology</i> , 2013, 190, 6004-6014.	0.8	6
72	Pathological Response and Immune Biomarker Assessment in Non-Small-Cell Lung Carcinoma Receiving Neoadjuvant Immune Checkpoint Inhibitors. <i>Cancers</i> , 2022, 14, 2775.	3.7	5

#	ARTICLE	IF	CITATIONS
73	Exposure to anti-PD-1 causes functional differences in tumor-infiltrating lymphocytes in rare solid tumors. <i>European Journal of Immunology</i> , 2019, 49, 2245-2251.	2.9	4
74	In Trans T Cell Tolerance Diminishes Autoantibody Responses and Exacerbates Experimental Allergic Encephalomyelitis. <i>Journal of Immunology</i> , 2008, 180, 1508-1516.	0.8	3
75	Genomic Correlates of Outcome in Tumor-Infiltrating Lymphocyte Therapy for Metastatic Melanoma. <i>Clinical Cancer Research</i> , 2022, 28, 1911-1924.	7.0	3
76	TIL therapy and anti-CTLA4: can they co-exist?. <i>Oncotarget</i> , 2019, 10, 1-2.	1.8	1
77	Identification of predictive biomarker signatures in melanoma tumors associated with response to tumor-infiltrating lymphocyte (TIL) therapy. , 2013, 1, .		0
78	Development of novel combinations of targeted and immunotherapies by understanding immune resistance using a high throughput assay of T cell mediated cytotoxicity. , 2013, 1, .		0
79	Interleukin-6 Blockade Abrogates Immunotherapy Toxicity and Promotes Tumor Immunity. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
80	Isolation and Maintenance of Tumor-Infiltrating Lymphocytes for Translational and Clinical Applications: Established Methods and New Developments. <i>Methods in Molecular Biology</i> , 2022, 2435, 43-71.	0.9	0